Clinical Study
Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies
Table 1
Baseline characteristics according with HLA antibodies.
| | | Anti-HLA antibodies
() | No anti-HLA antibodies
() | |
| | Age (y) | | | 0.2 | | Sex (females %) | 12 (38%) | 15 (11%) | <0.01 | | Pre-transplant CAD (%) | 16 (50%) | 65 (46%) | 0.7 | | Donor age (y) | | | 0.7 | | Donor sex (females %) | 5 (16%) | 40 (29%) | 0.1 | | Donor cause of death (stroke %) | 15 (48%) | 45 (33%) | 0.1 | | Pre-transplant heart surgery (%) | 13 (41%) | 42 (30%) | 0.2 | | Cold ischemic time | | | 0.7 | | Started on MMF versus AZA (%) | 3 (9%) | 32 (24%) | 0.05 |
|
|
